Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation clinical trial (NCT01894672). Contact the study team or your healthcare provider for specific answers.

Question 2

How does LGX818 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation clinical trial (NCT01894672). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from LGX818?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation clinical trial (NCT01894672). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits and tests during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation clinical trial (NCT01894672). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or my condition changes during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation clinical trial (NCT01894672). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation clinical trial (NCT01894672). Contact the study team or your healthcare provider for specific answers.

What this study is about